RECENT FUNDING ROUNDS
Company | Country | Profile | Funding round | Value | Date | |
---|---|---|---|---|---|---|
![]() |
Neurelis Inc | Neuroscience company. | Series D | USD 114,000,000 | ||
![]() |
Maridose LLC | Biotech - Cannabis R&D. We are a US DEA licensed manufacturer of Schedule 1 drugs. | Pre Seed | USD 150,000 | ||
![]() |
Gilgamesh Pharmaceuticals Inc | Novel psychedelic-Inspired therapeutics for treating mental illness. | Seed | |||
![]() |
3-V Biosciences Inc | Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. | Series B | USD 30,000,000 | ||
![]() |
Vyome Biosciences Pvt Ltd | Developer of medicines for treating skin diseases caused by resistant microbes. | Series C | USD 14,000,000 | ||
![]() |
Arcis Biotechnology Holdings Ltd | N/A | GBP 2,500,000 | |||
![]() |
FunkSac LLC | Provider of customer services and compliant packaging solutions for the legal cannabis industry; both medical and recreational markets. | N/A | |||
![]() |
23andMe Inc | DNA testing and genome sequencing firm. | Series E | USD 79,100,000 | ||
![]() |
3SBio Inc | IPO | HKD 5,510,000,000 | |||
![]() |
23andMe Inc | DNA testing and genome sequencing firm. | Grant | USD 1,400,000 | ||
![]() |
Merck & Co | Acquisition | USD 14,200,000,000 | |||
![]() |
Arecor Ltd | Developer of technology that is used in the formulation of biopharmaceuticals. | N/A | |||
![]() |
Zosano Pharma Inc | Debt | USD 3,030,000 | |||
![]() |
3-V Biosciences Inc | Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. | Series C | USD 20,000,000 | ||
![]() |
Tokai Pharmaceuticals Inc | Developer of prostate cancer drugs | Series E | USD 35,000,000 | ||
![]() |
Trevena Inc | Series C | USD 60,000,000 | |||
![]() |
Allecra Therapeutics | Developer of antibiotic treatments designed to combat multi drug-resistant gram-negative bacteria | Series A | EUR 15,000,000 | ||
![]() |
Aquinox Pharmaceuticals Inc | Developer of small molecule therapeutics for the treatment of inflammatory disease | Series C | |||
![]() |
Aquinox Pharmaceuticals Inc | Developer of small molecule therapeutics for the treatment of inflammatory disease | Series C | USD 18,000,000 | ||
![]() |
Kala Pharmaceuticals Inc | Developer of products that penetrate the mucosal barrier to treat a variety of severe diseases | Series A |
MOST ACTIVE INVESTORS
MOST ACTIVE ACQURERS
Pfizer Inc | US | 6 |
Ampersand Ventures | US | 3 |
Gilead Sciences Inc | US | 3 |
Abbott Laboratories | US | 2 |
F Hoffmann-La Roche Ltd | 1 | |
Emerging Capital Partners | US | 1 |
Allscripts Healthcare Solutions Inc | US | 1 |
Johnson & Johnson Innovation LLC | US | 1 |
Biogen Idec Inc | US | 1 |
GelTex Pharmaceuticals | US | 1 |
Pharmion Corp | US | 1 |
Corixa Corp | US | 1 |
Serologicals Corp | US | 1 |
Viatris | 1 | |
Bayer AG | DE | 1 |
Vets First Choice | 1 | |
Baxter International Inc | US | 1 |
Cubist Pharmaceuticals Inc | 1 | |
Biovitrum AB | SE | 1 |
Genzyme Corp | US | 1 |
Galapagos NV | BE | 1 |
Aquila Biopharmaceuticals Inc | 1 |
BEST FUNDED STARTUPS
Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases.
Novel small molecule, receptor-specific therapeutics company for the treatment of central nervous system, cardiovascular and renal diseases.
Advanced fight against drug resistant microbes by attacking novel targets with novel drugs.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases.
Developer of small molecule therapeutics for the treatment of inflammatory disease
Developer of products that penetrate the mucosal barrier to treat a variety of severe diseases
Developer of medicines for treating skin diseases caused by resistant microbes.
Developer of antibodies to reduce tissue damage and improve ventricular function associated with myocardial infarction